Aflibercept 8mg for new wet AMD patients
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests a higher dose of aflibercept given on a flexible schedule for people who have not yet been treated for wet age-related macular degeneration (nAMD). It aims to see if this approach is safe and effective at improving vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older.
- You have not received any prior treatment for wet AMD in the study eye.
- You have active wet AMD with fluid in or under the retina in the center of your vision.
- Your vision in the study eye is between 20/32 and 20/320 on a standard eye chart.
- If you or your partner could become pregnant, you agree to use effective contraception during and for 4 months after treatment.
- You do not have uncontrolled high blood pressure or other serious eye diseases like diabetic retinopathy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene therapy injection under the retina for people with wet age-related macular degeneration (AMD), which causes blurry vision from abnormal blood vessels. It aims to reduce the need for frequent eye injections by delivering a treatment that may help the eye produce its own medicine.
This study follows patients receiving aflibercept 8 mg injections in the eye to treat wet age-related macular degeneration (nAMD), a condition that blurs central vision. The goal is to understand how well this treatment works and its safety in routine medical practice.
This trial tests switching to a higher dose of aflibercept for people with wet age-related macular degeneration (AMD) who have already had several standard doses. It aims to see if a higher dose works better at keeping vision stable and reducing treatments.
This trial tests if switching to a higher dose of aflibercept (Eylea) can help people with wet age-related macular degeneration (AMD) who need frequent eye injections. If you've been on other anti-VEGF injections for over a year and still need them more often than every 12 weeks, this study might offer a new option.
This study tests a higher dose of the medicine aflibercept (brand name Eylea) in people who have already had at least three eye injections for wet age-related macular degeneration or diabetic macular edema. The goal is to see how well this stronger dose works in real-life conditions and how long its effects last.
This trial tests a higher dose of aflibercept (a drug that blocks abnormal blood vessel growth) for people with a specific form of wet age-related macular degeneration called polypoidal choroidal vasculopathy. The goal is to see if a personalized treatment plan with this stronger dose is safe and effective for those who have not been treated before.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.